| John C. Taylor |
John C. Taylor founded Aceragen, Inc. Presently, Mr. Taylor is Chief Executive Officer & Director at Idera Pharmaceuticals, Inc.
Mr. Taylor previously held the position of President, Chief Executive Officer & Director at Spyryx Biosciences, Inc., President, Chief Executive Officer & Director at Aceragen, Inc., Vice President-Business Development of Synageva BioPharma Corp. and Vice President-Business Development for Javelin Pharmaceuticals, Inc.
He received an undergraduate degree from Clemson University and a graduate degree from The Wharton School of the University of Pennsylvania. |
| John Taylor |
Founder of Aceragen, Inc., John Taylor is Chief Executive Officer at Idera Pharmaceuticals, Inc. and President, Chief Executive Officer & Director at Aceragen, Inc. (a subsidiary of Idera Pharmaceuticals, Inc.). |
| Daniel B. Soland |
Currently, Daniel B. Soland occupies the position of Chief Operating Officer & Senior Vice President for Idera Pharmaceuticals, Inc. He is also on the board of ACADIA Pharmaceuticals, Inc. and DBV Technologies SA.
In his past career Mr. Soland was Chief Executive Officer & Executive Director at uniQure NV, President & Chief Executive Officer for Epigenesis Pharmaceuticals LLC, VP & Director-Worldwide Marketing Operations at GSK Plc and Director-Worldwide Marketing Operations & VP at Corixa Corp. (a subsidiary of GSK Plc), President of Seqirus Vaccines Ltd., Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. and President-Chiron Vaccines at Chiron Corp.
He received an undergraduate degree from the University of Iowa. |
| Carl N. Kraus |
Founder of Arrevus, Inc., Carl N. Kraus currently is Chief Medical Officer at Idera Pharmaceuticals, Inc. and Chairman, President & Chief Executive Officer at Arrevus, Inc. (a subsidiary of Idera Pharmaceuticals, Inc.) and Medical Director of i3 Research, Inc.
In the past Dr. Kraus was Chief Medical Officer at Ology Bioservices, Inc.
Dr. Kraus received an undergraduate degree from Washington University School of Medicine. |
| John J. Kirby |
Currently, John J. Kirby holds the position of Chief Financial Officer & Senior Vice President at Idera Pharmaceuticals, Inc. He is also on the board of Delaware Museum of Natural History, Inc.
In the past he held the position of Chief Accounting Officer & Vice President for Shire ViroPharma, Inc., Assistant Controller at Endo Pharmaceuticals, Inc. and Regional Audit Director at AstraZeneca Pharmaceuticals LP.
Mr. Kirby received an undergraduate degree from Villanova University. |
| Daniel Salain |
Currently, Daniel Salain holds the position of Chief Operating Officer at Idera Pharmaceuticals, Inc. and Chief Operating Officer at Aceragen, Inc. (a subsidiary of Idera Pharmaceuticals, Inc.).
He previously held the position of Chief Operations & Technology Officer at Graybug Vision, Inc., Senior Vice President-Technical Operations at IVERIC bio, Inc., Vice President-Operations of Eurand Pharmaceuticals, Inc. and Vice President-Global Supply Chain & Manufacturing at Aptalis Pharma, Inc.
Mr. Salain received an undergraduate degree from the University of Indianapolis. |
| James Arthur Geraghty |
James Arthur Geraghty is an American businessperson who has been at the helm of 8 different companies. He holds the position of Chairman for Pieris Pharmaceuticals, Inc., Chairman at Orchard Therapeutics Plc, Chairman of Orchard Therapeutics (Europe) Ltd. (a subsidiary of Orchard Therapeutics Plc) and Chairman of Juniper Pharmaceuticals, Inc. He is also on the board of 7 other companies.
He previously occupied the position of Senior Vice President at Third Rock Ventures LLC, Chairman for Juniper Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer for rEVO Biologics, Inc., President of Genzyme Europe BV, Senior Vice President-International Development at Genzyme Corp., Senior VP-Strategy & Business Development at Sanofi SA and Vice President-Marketing & Strategic Planning at Caremark International, Inc.
He received a graduate degree from the University of Pennsylvania, an undergraduate degree from Georgetown University and a graduate degree from Yale Law School. |
| Andrew R. Jordan |
Andrew R. Jordan founded Guilford Pharmaceuticals, Inc. Mr. Jordan is Chief Strategy Officer for Idera Pharmaceuticals, Inc.
He previously was EVP-Finance & Administration at Guilford Pharmaceuticals, Inc., Chief Financial & Business Officer at Infraredx, Inc., Chief Financial Officer of KPMG LLP and Principal at Odyssey Pharmaceuticals.
Andrew R. Jordan received an MBA from Rutgers State University of New Jersey. |
| Vincent J. Milano |
Currently, Vincent J. Milano occupies the position of Chairman of Idera Pharmaceuticals, Inc. and Chairman for Life Science Cares Philadelphia. Mr. Milano is also on the board of BioCryst Pharmaceuticals, Inc., Biotechnology Innovation Organization and Aclaris Therapeutics, Inc.
He previously was Chairman, President & Chief Executive Officer of Shire ViroPharma, Inc., Senior Manager at KPMG LLP and Chairman of Life Sciences Pennsylvania.
Vincent J. Milano received an undergraduate degree from Rider University. |
| Carol Anne Schafer |
Currently, Carol Anne Schafer occupies the position of Managing Partner at Hyphen Advisors LLC. She is also on the board of 5 other companies.
In the past Ms. Schafer occupied the position of VP-Finance, Business Development & Communications at Lexicon Pharmaceuticals, Inc., MD, VP & Head-Equity Capital Markets at J.P. Morgan & Co., Inc. (Old) and Vice Chairman-Equity Capital Markets at Wells Fargo Securities LLC.
She received an undergraduate degree from Boston College and an MBA from The Leonard N Stern School of Business. |
| Maxine Gowen |
Founder of Trevena, Inc., Maxine Gowen presently is Chairman at Passage Bio, Inc. She is also on the board of 6 other companies.
She previously occupied the position of Director at Trevena, Inc., SVP-Center Excellence for External Drug Discovery at GSK Plc and Managing Partner at GSK Equity Investments Ltd (a subsidiary of GSK Plc), Senior Vice President for Center of Excellence For External Drug Discovery, VP-Drug Discovery & Musculoskeletal Diseases at GSK Plc and Managing Partner at GSK Equity Investments Ltd (a subsidiary of GSK Plc) and Head-Bone Cell Biology Group at the University of Bath.
She received an undergraduate degree from the University of Bristol, a doctorate from The University of Sheffield, an MBA from The Wharton School of the University of Pennsylvania and a doctorate from the University of Bath. |
| Cristina Csimma |
Founder of Cydan II, Inc., Cristina Csimma is a businessperson who has been at the helm of 5 different companies and currently is Chairman of Caraway Therapeutics, Inc. She is also on the board of Idera Pharmaceuticals, Inc., Syncona Ltd. and Palisade Bio, Inc.
In her past career Dr. Csimma occupied the position of Director at Cydan II, Inc. and President & Chief Executive Officer for Cydan LLC (a subsidiary of Cydan II, Inc.), Chairman of Forendo Pharma Oy, Executive Chairman for Exonics Therapeutics, Inc., Independent Director at Juniper Pharmaceuticals, Inc., Genetics Institute at Genetics Institute LLC, Vice President-Drug Development at Virdante Pharmaceuticals, Inc., Director-Clinical Research & Development at Wyeth-Ayerst Research, Senior Director-Translational Research at Pfizer Pharmaceuticals, Inc., Principal at Clarus Ventures LLC and Principal at Dana-Farber Cancer Institute, Inc.
She received a graduate degree from Northeastern University and an undergraduate degree and a doctorate from Massachusetts College of Pharmacy & Health Science. |
| Mark Alan Goldberg |
Mark Alan Goldberg is on the board of ImmunoGen, Inc. and 5 other companies. In his past career he was Principal at The Brigham & Women's Hospital, Inc., Senior Vice President-Clinical Research at Genzyme Corp., Executive VP-Global Medical & Regulatory Strategy at Synageva BioPharma Corp., Chief Medical Officer for CANbridge Life Sciences Ltd., Principal at Dana-Farber Cancer Institute, Inc. and Associate Professor at Harvard Medical School.
Dr. Goldberg received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School. |
| Michael R. Dougherty |
Michael R. Dougherty is a businessperson who has been at the head of 5 different companies. Mr. Dougherty is on the board of Idera Pharmaceuticals, Inc., Trevena, Inc., Altherx, Inc. and Viralclear Pharmaceuticals, Inc.
In the past he held the position of President & Chief Executive Officer at Genaera Corp., Chief Executive Officer & Director at Kalidex Pharmaceuticals, Inc., Executive Chairman of Celator Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Adolor Corp., President & Chief Operating Officer at Genomics Collaborative, Inc. and Chief Financial Officer & Senior Vice President of Centocor, Inc.
Mr. Dougherty received an undergraduate degree from Villanova University. |
